Compounds > acetic acid [6-ethyl-2-methyl-3-(1-methyl-2-benzimidazolyl)-4-oxo-1-benzopyran-7-yl] ester
Page last updated: 2024-12-10

acetic acid [6-ethyl-2-methyl-3-(1-methyl-2-benzimidazolyl)-4-oxo-1-benzopyran-7-yl] ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3092570
CHEMBL ID1329101
CHEBI ID92290

Synonyms (28)

Synonym
smr000686159
MLS001242385
[6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxochromen-7-yl] acetate
EU-0040874
ml048
UNM000003536701 ,
OPREA1_151337
OPREA1_681432
AKOS000525202
CHEMBL1329101
HMS2231A24
6-ethyl-2-methyl-3-(1-methyl-1h-benzimidazol-2-yl)-4-oxo-4h-chromen-7-yl acetate
STK922580
3570-0208 [pmid:19807662]
HMS3372G14
gtpl5828
[6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxidanylidene-chromen-7-yl] ethanoate
bdbm40404
acetic acid [6-ethyl-4-keto-2-methyl-3-(1-methylbenzimidazol-2-yl)chromen-7-yl] ester
cid_3092570
acetic acid [6-ethyl-2-methyl-3-(1-methyl-2-benzimidazolyl)-4-oxo-1-benzopyran-7-yl] ester
sr-01000456743
SR-01000456743-1
CHEBI:92290
2-methyl-3-(1-methyl-2-benzimidazolyl)-6-ethyl-7-acetoxychromone
Q27073547
210639-90-0
DTXSID901349026
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
chromonesA chromenone that consists of a 1,4-benzopyrone skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acid sphingomyelinaseHomo sapiens (human)Potency15.848914.125424.061339.8107AID504937
TDP1 proteinHomo sapiens (human)Potency5.84330.000811.382244.6684AID686978; AID686979
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency56.23410.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fMet-Leu-Phe receptorHomo sapiens (human)Ki0.10000.04200.07100.1000AID594625
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fMet-Leu-Phe receptorHomo sapiens (human)KI_MICROM0.30000.30000.30000.3000AID724
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
phospholipase C-activating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
chemotaxisfMet-Leu-Phe receptorHomo sapiens (human)
signal transductionfMet-Leu-Phe receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
nitric oxide mediated signal transductionfMet-Leu-Phe receptorHomo sapiens (human)
complement receptor mediated signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationfMet-Leu-Phe receptorHomo sapiens (human)
inflammatory responsefMet-Leu-Phe receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein-coupled receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
G protein-coupled receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
N-formyl peptide receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
scavenger receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
protein bindingfMet-Leu-Phe receptorHomo sapiens (human)
RAGE receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
complement receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmfMet-Leu-Phe receptorHomo sapiens (human)
plasma membranefMet-Leu-Phe receptorHomo sapiens (human)
membranefMet-Leu-Phe receptorHomo sapiens (human)
secretory granule membranefMet-Leu-Phe receptorHomo sapiens (human)
azurophil granule membranefMet-Leu-Phe receptorHomo sapiens (human)
ficolin-1-rich granule membranefMet-Leu-Phe receptorHomo sapiens (human)
plasma membranefMet-Leu-Phe receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID594625Antagonist activity at FPR12011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Discovery of small molecule human FPR1 receptor antagonists.
AID1345827Human FPR1 (Formylpeptide receptors)2009Current topics in medicinal chemistry, , Volume: 9, Issue:13
Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		2.0610pyrazolidines;
sulfoxide		uricosuric drug
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510